Cardiovascular disease (CVD) and cancer are among the leading causes of morbidity and
mortality globally, and these conditions are increasingly recognized to be fundamentally …

Advances in cancer therapeutics have led to dramatic improvements in survival, now
inclusive of nearly 20 million patients and rising. However, cardiovascular toxicities …

Advances in cancer therapeutics have revolutionized survival outcomes in patients with
cancer. However, cardiovascular toxicities associated with specific cancer therapeutics …

Background While the impacts of social and environmental exposure on cardiovascular risks
are often reported individually, the combined effect is poorly understood. Methods and …

Addressing the need for more equitable cardio-oncology care requires attention to existing
disparities in cardio-oncologic disease prevention and outcomes. This is particularly …

Baseline cardiovascular assessment before the initiation of potentially cardiotoxic cancer
therapies is a key component of cardio-oncology, aiming to reduce cardiovascular …

Background Relationships between the social determinants of health (SDOH) and
cardiovascular health (CVH) of cancer survivors are underexplored. Objectives This study …

Background This study aims to quantify Black–White inequities in cardiovascular disease
(CVD) mortality among US survivors of 18 adult-onset cancers and the extent to which these …

Cardiologists are encountering a growing number of cancer patients with ischaemic heart
disease (IHD). Several factors account for the interrelationship between these two …

Objectives Recent research has investigated the factors associated with the prevalence of
opioid use disorder (OUD) among older adults (65+), which has rapidly increased in the past …